Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641441 | 0.89 | VDR (0.84) | VDRPPARGPPARDPPARAMAOB | |
| SCHEMBL4881104 | 0.85 | VDR (0.77) | VDRPPARGPPARDPPARAMAOB | |
| SCHEMBL4620770 | 0.81 | VDR (0.66) | VDR | |
| SCHEMBL6564164 | 0.81 | VDR (0.77) | VDRPPARDMAOB | |
| SCHEMBL2639763 | 0.80 | VDR (0.67) | VDRPPARGPPARDPPARAMAOB | |
| SCHEMBL229168 | 0.80 | VDR (1.00) | VDRPPARGPPARDPPARAMAOB | |
| SCHEMBL6564192 | 0.79 | VDR (0.68) | VDRPPARDMAOB | |
| SCHEMBL2890399 | 0.78 | VDR (0.73) | VDRPPARGPPARDPPARA | |
| SCHEMBL4894574 | 0.77 | VDR (0.66) | VDRPPARGPPARDPPARA | |
| SCHEMBL2855063 | 0.77 | VDR (1.00) | VDRCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | claimed |
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | CYP24A1, VDR, CYP2R1 | VDR 2/4885SHBG 1998/4885PPARG 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.